Services
Evidence, Access & Pricing
Our team of experts work across functions to develop locally nuanced and comprehensively global strategies spanning evidence, value, access and pricing.
The pharma-biotech landscape is rapidly evolving, creating a range of challenges for manufacturers who need to generate evidence, communicate value, and optimize their products’ pricing and access.
Trinity’s Evidence, Value, Access and Pricing team team has unparalleled experience across geographies and therapeutic areas. We work across the product lifecycle, addressing needs at a global & local level.
The Trinity Difference:
- An integrated approach across all offerings and areas of Evidence, Value, Access, and Pricing expertise
- In-depth therapeutic area and product modality experience, including cell and gene therapies
- Scientifically rigorous methodologies and real-world studies to drive impactful evidence and publications
- Compelling real-world data analytics and modeling expertise
- Deep market access expertise, leveraging extensive knowledge of access trends / policy changes
- Global list and net pricing methodological expertise, including in-depth U.S. payer / provider contracting
- First-hand negotiation experience translated into both our strategies and our negotiation training program
Products
We have supported the evidence, value, access & pricing strategy of the majority of innovative launches over the last decade, and have experience spanning across most therapeutic areas.
Experts
Our team consists of experts with in-depth local knowledge and native language skills that contribute towards the development of Trinity’s Geo-Knowledge Resource Hubs which span across all major geographies.
Network
We have an extensive in-house payer network, and access to key stakeholders ranging from national government authorities to local hospital and practice administrators / executives.
Impact
We have a vast portfolio of successful evidence generation and value demonstration studies which have translated into access and commercial success.
Geo-Knowledge Resource Hubs
Trinity’s Geo-Knowledge Resource Hubs distill deep market knowledge, cultivate best practices, and generate thought leadership.
Centers of Excellence
Cell and Gene Therapy
Cell and gene therapies (CGTs) represent the next major breakthrough in the development of innovative treatments for severe diseases, with the possibility to address the root causes of disease and provide lasting clinical value, and in some cases, a cure.
Digital Therapeutics and Health Technology
Digital health technologies are evolving rapidly and are playing an increasingly significant role in both the companion diagnostic and treatment paradigms. Trinity’s experts draw upon their deep understanding of access and reimbursement decision-making for traditional therapeutics to identify and analyze the most impactful events and landscape shifts in the digital space.
Latest Evidence, Value, Access and Pricing Intelligence
Market Access Opportunities & Challenges: An Exploration of Three Global Trends
Now Available On Demand: Join Trinity Life Sciences’ Evidence, Value, Access and Pricing and Cell & Gene Therapy experts for a deeper look at the market access trends that will present the most impactful opportunities and challenges for life sciences organizations in 2023. This webinar will expand upon the trends discussed in the recently released […]
Dawn of a New Era: Evolving Needs, Solutions and Technology in U.S. HEOR
The U.S. health economics and outcomes research (HEOR) field has seen many changes over the last decade, including significant growth driven by payers, regulators and clinicians who are increasingly looking to Real-World Evidence (RWE) as a valuable source for patient-level data. […]
HTA/Reimbursement Evolution and Priorities for Assessment in a Value-Based Healthcare Environment in Latin America
This session will discuss trends in the HTA/Reimbursement environment in Latin America and the drivers for value-based health care (VBHC) implementation within the region. The potential benefits of VBHC […]
France Pilots Opportunity to Increase Speed to Reimbursement for Select Innovative Products
French president Emmanuel Macron announced a two-year trial that will allow pharmaceutical products that receive an ‘Amélioration du Service Médical Rendu’ (ASMR) rating of IV or better to get reimbursement […]
The Humira Case: Exploring the Blockbuster Ahead of United States Biosimilar Launch
Up to nine biosimilar versions of Humira (adalimumab) are expected to launch in 2023 in the United States, following settlements between AbbVie and their respective manufacturers. In contrast, biosimilar versions of adalimumab have been available in most countries […]
Meet our Evidence, Value, Access and Pricing Experts
Mónica Martín de Bustamante
Senior Partner,
Evidence, Value, Access & Pricing
Ms. Martin de Bustamante’s career has focused on pharmaceutical global pricing and market access issues for biopharmaceutical and pharmaceutical products. Her time has been apportioned between the mature and emerging markets, with deep expertise in the USA, EU5, CAN, and JPN. Ms. Martin de Bustamante has worked across the major therapeutic areas (oncology, cardiovascular, neurology, […]
Robert Albarano
Managing Director
Rob is a Managing Director in Trinity’s Evidence, Value, Access, and Pricing practice. Prior to joining Trinity, Rob was a Managing Director (Partner) at L.E.K. Consulting. Rob has 20+ years of healthcare strategy consulting experience, including ~15 years of Market Access and commercial strategy experience. His Market Access experience includes developing launch, pricing, innovative and […]
Valeria Boers Trilles
Director,
Value, Access & Pricing
Ms. Boers is a Director in Trinity’s Value, Access & Pricing practice. Prior to joining Trinity, Ms. Boers was part of the CBPartners team and focused her experience on pricing and market access engagements, proving strategic support to optimize value communication, product positioning, IRP-based launch sequence and pricing opportunity across a range of therapeutic areas, […]
Christian Frois
Partner,
Value, Access & Pricing
Christian is a recognized and widely published expert on pricing, contracting, market access and payer evidence strategy. He leads Trinity’s pricing, market access, reimbursement and contracting (PARC) group, and has supported the development of PARC strategies for more than 50 assets in the US and ex-US.
Andrew Gould
Partner,
Value, Access & Pricing
Mr. Gould is a Managing Director in Trinity’s Value, Access, and Pricing practice. Prior to joining Trinity, he led CBPartners’ U.S. Center of Excellence and focused on managed markets strategy engagements. His experience has emphasized the development of numerous pricing and access strategies for both pre-launch and in-line assets within the U.S. Specifically, Mr. Gould […]
John Greenaway
Partner,
Value, Access & Pricing
John co-leads our San Francisco office and team and drives growth in our strategic advisory service offering in Pricing, Access, Reimbursement, and Contracting (PARC). Since 1999, John has been leading strategic contracting initiatives, brand planning, forecasting, and product launch strategies to inform customers’ data-driven strategic decision making with market research, quantitative analysis, and financial modeling. […]
Nandini Hadker
Partner,
Evidence Strategy
An economist by training, Nandini is a Partner at Trinity Life Sciences with over two decades of experience in custom research and strategy consulting. She is seasoned at helping clients identify what evidence will be crucial in driving their product’s success, generating that evidence using publication-grade research, and pulling the insights through scientific dissemination. She […]
Maximilian Hunt
Partner,
Value, Access & Pricing
Mr. Hunt is a Partner in Trinity’s Value, Access, and Pricing practice. His experience as a global life sciences strategy consultant spans all stages of product development and a wide range of therapeutic areas, including oncology, inflammatory conditions, rare diseases, and cell and gene therapies. Prior to joining Trinity, Mr. Hunt’s engagement work at CBPartners targeted a variety of commercial business issues related […]
Miguel Martín de Bustamante
Partner,
Value, Access & Pricing
Prior to joining Trinity, Mr. Martín de Bustamante worked across CBPartners’s practices, with a focus on Value, Access, and Pricing. He developed expertise across many related areas, including innovative contracting and access models, strategic product / portfolio positioning, IRP and commercial opportunity based launch sequencing, as well as value positioning across various therapeutic areas. He […]
Matt O’Hara
Partner,
Evidence Strategy
Matt joins Trinity with over 20 years of life sciences consulting experience. During his career, Matt has worked with both pharmaceutical and medical device clients across business/commercial strategy (pricing, market access, product portfolio rationalization, acquisitions, Intellectual Property, and market insights), HEOR (value proposition development, evidence generation planning, and literature reviews, budget impact and comparative effectiveness […]
Bami Oshinowo
Partner, Value, Access & Pricing
& London Office Lead
Prior to joining Trinity, Ms. Oshinowo led engagement work within the Value, Access and Pricing Practice and drove the Early VAP & CP Centre of Excellence at CBPartners. Her primary expertise is on early-stage pipeline issues related to commercial strategy, including competitive positioning, pricing, market access and trial design optimization. Her geographical expertise includes the USA […]
Shinkyu Park
Director
Mr. Park is a Director in Trinity’s Value, Access & Pricing practice. Prior to joining Trinity, Mr. Park’s work at CBPartners was primarily focused on pricing, market access, and value demonstration engagements in support of strategic planning with a variety of biopharmaceutical clients. Mr. Park has led many global (including USA, EU, APAC and LatAm) […]
Julia Pikus
Principal,
Value, Access & Pricing
Ms. Pikus is a Principal in Trinity’s Value, Access & Pricing practice. Prior to joining Trinity, Ms. Pikus led engagement work within the Value, Access and Pricing Practice and drove the Cell and Gene Therapy Centre of Excellence at CBPartners. In this capacity, Ms. Pikus supported a range of qualitative and quantitative engagements to inform […]
Jeff Skaar
Managing Director,
Evidence Strategy
Jeff supports pharmaceutical, device, and diagnostic companies in demonstrating and communicating the value of their products. His work is informed by broader experiences in market access and business and clinical strategy, allowing him to craft health economics and outcomes research solutions that dovetail with overall strategic plans for products across their life cycle stages. In […]
If you have any questions, we’re here to answer them.
We look forward to helping identify solutions for you.